Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
SAN DIEGO, May 08, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 15, 2017 at 5:00 p.m. ET to report its first quarter 2017 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 18632775. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
